What's in Placebos: Who Knows? Analysis of Randomized, Controlled Trials

BACKGROUND No regulations govern placebo composition. The composition of placebos can influence trial outcomes and merits reporting. PURPOSE To assess how often investigators specify the composition of placebos in randomized, placebo-controlled trials. DATA SOURCES 4 English-language general and internal medicine journals with high impact factors. STUDY SELECTION 3 reviewers screened titles and abstracts of the journals to identify randomized, placebo-controlled trials published from January 2008 to December 2009. DATA EXTRACTION Reviewers independently abstracted data from the introduction and methods sections of identified articles, recording treatment type (pill, injection, or other) and whether placebo composition was stated. Discrepancies were resolved by consensus. DATA SYNTHESIS Most studies did not disclose the composition of the study placebo. Disclosure was less common for pills than for injections and other treatments (8.2% vs. 26.7%; P = 0.002). LIMITATION Journals with high impact factors may not be representative. CONCLUSION Placebos were seldom described in randomized, controlled trials of pills or capsules. Because the nature of the placebo can influence trial outcomes, placebo formulation should be disclosed in reports of placebo-controlled trials.

[1]  D. Moher,et al.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. , 2010, Obstetrics and gynecology.

[2]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.

[3]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[4]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[5]  B. Golomb Doctoring the Evidence: The Case Against Lying to Patients about Placebos , 2009, The American journal of bioethics : AJOB.

[6]  L. Wedlake,et al.  Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study. , 2008, European journal of cancer.

[7]  M. Covas Bioactive effects of olive oil phenolic compounds in humans: reduction of heart disease factors and oxidative damage , 2008, Inflammopharmacology.

[8]  Ian M Paul,et al.  Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. , 2007, Archives of pediatrics & adolescent medicine.

[9]  R. Eccles Mechanisms of the placebo effect of sweet cough syrups , 2006, Respiratory Physiology & Neurobiology.

[10]  K. Cullinen Olive oil in the treatment of hypercholesterolemia. , 2006, Medicine and health, Rhode Island.

[11]  Roger B. Davis,et al.  Sham device v inert pill: randomised controlled trial of two placebo treatments , 2006, BMJ : British Medical Journal.

[12]  J. Marrugat,et al.  Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized, crossover, controlled, clinical trial. , 2005, Atherosclerosis.

[13]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[14]  H. Joensuu,et al.  Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  R. Palmer When are medication side effects due to the nocebo phenomenon? , 2002, JAMA.

[16]  K. Streitberger,et al.  Introducing a placebo needle into acupuncture research , 1998, The Lancet.

[17]  N. Black CONSORT , 1996, The Lancet.

[18]  B. Golomb Paradox of placebo effect , 1995, Nature.

[19]  D. Schaid,et al.  Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. , 1990, Journal of the National Cancer Institute.

[20]  D. S. Holmes,et al.  Influence of aerobic exercise on depression. , 1984, Journal of personality and social psychology.

[21]  E. Hutchinson,et al.  Controlled trial of clofibrate in cerebral vascular disease. , 1972, Atherosclerosis.

[22]  Ischaemic Heart Disease: A Secondary Prevention Trial Using Clofibrate , 1971 .

[23]  N Engl,et al.  A controlled trial of arthroscopic surgery for osteoarthritis of the knee , 2005 .

[24]  Emmett T. Cunningham,et al.  VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .

[25]  B. Golomb When are medication side effects due to the nocebo phenomenon? , 2002, JAMA.

[26]  Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. , 1971, British medical journal.